New hope for patients with rare, Life-Threatening blood vessel disease
NCT ID NCT07268521
Summary
This study is testing a drug called obinutuzumab for people with a rare and serious autoimmune disease called cryoglobulinemia vasculitis, where abnormal proteins damage blood vessels. It is specifically for patients whose disease did not improve with or who could not tolerate the standard treatment, rituximab. The goal is to see if this new drug can better control the disease and reduce symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOGLOBULINEMIC VASCULITIS (CV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.